Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 24, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections

JERSEY CITY, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
August 08, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update

Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078 Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As...
August 04, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference

JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference...
August 01, 2016 08:00 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis

Oral Dose of SCY-078 That Achieves Target Exposure Identified SCY-078 Safe and Well-Tolerated Antifungal Clinical Activity of SCY-078 Further Confirmed JERSEY CITY, N.J., Aug. 01, 2016 (GLOBE...
July 13, 2016 08:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited

JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based...
July 06, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald’s 2nd Annual...
June 21, 2016 09:15 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and...
June 20, 2016 16:02 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants...
June 20, 2016 08:00 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections

SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humansFungicidal activity of SCY-078 demonstrated against multiple Candida species, including...
June 10, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016

JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the...